BDBM618999 US20230295110, Compound 31.::US20230295110, Compound 47.

SMILES C[C@H](NC(=O)c1ncc(-c2cnn(c2)-c2ccccc2)c(C)c1O)C(O)=O

InChI Key InChIKey=REMUREJFNJSHSC-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 618999   

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618999(US20230295110, Compound 47. | US20230295110, Compo...)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618999(US20230295110, Compound 47. | US20230295110, Compo...)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618999(US20230295110, Compound 47. | US20230295110, Compo...)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618999(US20230295110, Compound 47. | US20230295110, Compo...)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618999(US20230295110, Compound 47. | US20230295110, Compo...)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618999(US20230295110, Compound 47. | US20230295110, Compo...)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent